Par Pharmaceutical Companies Inc

Par Pharmaceutical Companies — Investor Day (September 2007)

52 slides from Par Pharmaceutical Companies's investor day presentation, Sep 28, 2007

  1. Slide 1: Par Pharmaceutical Analyst / Investor Day

    Slide 1: Par Pharmaceutical Analyst / Investor Day

    Focus - Execution - Value Par Pharmaceutical Analyst / Investor Day September 28, 2007

  2. Slide 2: Safe Harbor Statement

    Slide 2: Safe Harbor Statement

    Safe Harbor Statement Certain statements in this presentation constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. To the extent any statements made in this presentation contain information that is not historical, these statements are es

  3. Slide 3: Today's Agenda

    Slide 3: Today's Agenda

    Today's Agenda Par's Strategy Operational Excellence Generic Business Branded Business Financial Update Looking Ahead

  4. Slide 4: Par's Creed

    Slide 4: Par's Creed

    Par's Creed WE ANSWER TO PATIENTS, to whom more than one million Par prescriptions are dispensed each week in the U.S. Therefore, we will assure our products are scientifically sound and of uncompromising quality. In a world with significant unmet medical needs, we will always remember that the pati

  5. Slide 5: Par's Strategy

    Slide 5: Par's Strategy

    Par's Strategy Patrick G. LePore Chairman, CEO and President

  6. Slide 6: Par at a Glance

    Slide 6: Par at a Glance

    Par at a Glance Develops, manufactures and markets generic drugs and innovative proprietary pharmaceuticals for specialty markets Generated $725 million in revenues in 2006 in two distinct divisions Generics 2006 revenues of $676 million 85 marketed product families 45 ANDAs Expanding pipeline Stron

  7. Slide 7: Strong, Experienced Management Team

    Slide 7: Strong, Experienced Management Team

    Strong, Experienced Management Team Patrick LePore President and CEO 30 years in pharma, including Cardinal Health, Boron LePore and Hoffmann-La Roche Jerry Martino EVP and COO 23 years in pharma and finance, including 12 at Schering-Plough Veronica Lubatkin EVP and CFO 22 years in pharma and financ

  8. Slide 8: Key Accomplishments To Date

    Slide 8: Key Accomplishments To Date

    Key Accomplishments To Date Strengthened management structure Refocused R&D 8 potential first-to-files during the last 12 months Terminated non-core assets 9 generic launches during the last 12 months Megace ES sales annualizing at over $75 million In-licensed 3 supportive care branded products Stre

  9. Slide 9: Refocusing Our Strategy

    Slide 9: Refocusing Our Strategy

    Refocusing Our Strategy Generics Focus on fewer, better products with higher barriers to entry Greater emphasis on internal product development First-to-files Leverage sales and marketing strength (AG opportunities) Focused on profitability Branded In-license late stage supportive care products Leve

  10. Slide 10: Building Long-Term Value

    Slide 10: Building Long-Term Value

    Building Long-Term Value DIFFERENTIATING FACTORS People Operational Excellence Proven Execution Strategic Focus

  11. Slide 11: Operational Excellence

    Slide 11: Operational Excellence

    Operational Excellence Gerard A. Martino Executive Vice President and COO

  12. Slide 12: Taking Action to Drive Execution

    Slide 12: Taking Action to Drive Execution

    Taking Action to Drive Execution Slice 9 East 16 16 16 16 PEOPLE Business Development R&D Supply Chain Financial Systems and Controls Continued strength in sales and marketing Experienced leadership team Refocused business development and R&D Enhanced processes and controls Working collaboratively

  13. Slide 13: Generic Business Review

    Slide 13: Generic Business Review

    Generic Business Review Paul V. Campanelli Executive Vice President and President, Generics Division

  14. Slide 14: Leading Generics Business

    Slide 14: Leading Generics Business

    Leading Generics Business Leading mid-size U.S. manufacturer and distributor of generic pharmaceuticals Ranked 7th in U.S. by sales1 Generated record revenues of $676 million in 2006 Develops products internally and in partnership with other pharmaceutical companies Portfolio includes 85 marketed pr

  15. Slide 15: Highly Regarded Generic Competitor

    Slide 15: Highly Regarded Generic Competitor

    Highly Regarded Generic Competitor Successful track record of partnerships Leverage business development, licensing and legal expertise Strong reputation for sales & marketing Excellent track record for successful product launches Distributing to top U.S. retail chains, wholesalers, distributors, ma

  16. Slide 16: Evolving U.S. Generics Trends

    Slide 16: Evolving U.S. Generics Trends

    Evolving U.S. Generics Trends Increasing number of companies filing ANDAs Over 36 new companies filed ANDAs over the last 18 months Emergence of low-cost global generics companies into U.S. market Lower R&D and manufacturing costs Generic companies pursuing international M&A opportunities Lower cost

  17. Slide 17: Addressing Market Dynamics

    Slide 17: Addressing Market Dynamics

    Addressing Market Dynamics Strategic product selection Focus on fewer, better products with higher barriers-to-entry High-profit, first-to-file and other opportunities R&D programs focused on winning target first-to-files Greater emphasis on internal product development Strategically select external

  18. Slide 18: Strategy Yielding Wins

    Slide 18: Strategy Yielding Wins

    Strategy Yielding Wins 15 first-to-file opportunities 7 first-to-file opportunities submitted to USFDA in 2007 year-to-date Ratio of first-to-files/ANDAs has increased from 6% in 2005 to 70% in 2007 36 products currently in development Shift to internal development programs ANDAs from internal devel

  19. Slide 19: Promising Pipeline

    Slide 19: Promising Pipeline

    Promising Pipeline Generic Product / Trade Name Brand Sales (in millions) MAT 06/07 ANDA Filer ANDA Filed Status Diazepam rectal gel / Diastat(r) $74 Par (Barr to market) 09/03 Settlement pending Sumatriptan vials and kit / Imitrex(r) $213 Par (Spectrum) 10/04 Settlement reached / launch 2008 Alpraz

  20. Slide 20: Recent Product Launches

    Slide 20: Recent Product Launches

    Recent Product Launches Par Other Market Share 0.56 0.44 44% 56% 51% Metoprolol ER 25 mg tabs / Toprol XL(r) Propranolol ER / Inderal LA(r) Source: IMS Health (NPA September 14, 2007 Weekly TRx Generic Data) Par Other Market Share 0.57 0.43 43% 57% Metoprolol ER 100/200 mg tabs / Toprol XL(r) Par Ot

  21. Slide 21: Well-Positioned to Successfully Execute Strategy

    Slide 21: Well-Positioned to Successfully Execute Strategy

    Well-Positioned to Successfully Execute Strategy Restructured and refocused R&D Continue to focus on bringing to market differentiated, hard to manufacture products Shift product mix to predominantly internal R&D Generate top tier growing profit margins and significant cash flows Strengthened positi

  22. Slide 22: Branded Business Review

    Slide 22: Branded Business Review

    Branded Business Review John A. MacPhee Executive Vice President and President, Branded Products Division

  23. Slide 23: Promising Branded Division

    Slide 23: Promising Branded Division

    Promising Branded Division Branded Division launched in 2005 with approval of Megace ES Megace ES conceived & developed by Par Generics Division Branded Division today Strong commercial infrastructure Foundational product annualizing >$75M (Q2 07) in net sales and growing Three Phase III pipeline pr

  24. Slide 24: Branded Strategy at Work in 2007

    Slide 24: Branded Strategy at Work in 2007

    Branded Strategy at Work in 2007 Established Megace ES as foundational product Focused our internal development program Leveraged commercial infrastructure Built pipeline Generated ~$19M in Q2 07 net sales; RXs continue to grow Divested PAR-101 and reduced R&D infrastructure Co-promotion of AndroGel

  25. Slide 25: Introducing Strativa Pharmaceuticals

    Slide 25: Introducing Strativa Pharmaceuticals

    Building a high-growth proprietary pharmaceutical business Initial therapeutic focus: Supportive care (Oncology & HIV) and select oncologicals Commercial excellence: Sales and marketing expertise, management and execution Fully-deployed commercial infrastructure 3rd party payer / reimbursement exper

  26. Slide 26: Significant Commercial Capabilities

    Slide 26: Significant Commercial Capabilities

    Significant Commercial Capabilities President, Branded Products Division Senior VP, Sales & Marketing 2 Area Directors and 9 Regional Business Directors Senior Director, Managed Markets 92 person specialty sales force 17 person long-term care sales force 10 person managed markets group 12 marketing,

  27. Slide 27: Why Supportive Care?

    Slide 27: Why Supportive Care?

    Why Supportive Care? Shift in trajectory Patients are living longer with HIV / AIDS / Cancer Increasing complications From living with disease and from treatments for the disease Patients and healthcare providers have unique needs Better served by focused and dedicated specialty pharmaceutical compa

  28. Slide 28: HIV/Oncology: Concentrated Markets

    Slide 28: HIV/Oncology: Concentrated Markets

    HIV/Oncology: Concentrated Markets 10 9 8 7 6 5 4 3 HIV Prescribers 71 129 180 243 324 448 652 1071 10 9 8 7 6 5 4 3 Oncologists 343 562 761 964 1241 1578 1506 1258 11,000 physicians represent 80% of prescription market * Market defined by IMS as misc anti-neoplastics

  29. Slide 29: HIV/Oncology Supportive Care: Key Customers

    Slide 29: HIV/Oncology Supportive Care: Key Customers

    HIV/Oncology Supportive Care: Key Customers Treaters 3,000 AIDS Specialists 8,000 Oncologists 12,000 Select Internists 2,000 Pain Specialists 25,000 MDs Influencers Oncology Nurses Dieticians Advocacy Groups Specialty Pharmacies Payers/Customers Commercial Plans Part D Plans Medicaid ADAP Oncology G

  30. Slide 30: Strativa: An Attractive Partner

    Slide 30: Strativa: An Attractive Partner

    Strativa: An Attractive Partner Specialty products focus and expertise Proven success (Megace ES) Full sales and marketing support, including reimbursement Therapeutic expertise and know-how Medical affairs and regulatory support Specialty company focus backed by Par Pharmaceutical's resources Acces

  31. Slide 31: Accelerated Business Development

    Slide 31: Accelerated Business Development

    Accelerated Business Development Dedicated business development resources Focused product targeting strategy Proprietary, single source, U.S.-focused RXs Currently marketed or late-stage development Fulfill unmet medical needs / unique selling proposition Not large enough to meet critical mass requi

  32. Slide 32: Rigorous Due Diligence Process

    Slide 32: Rigorous Due Diligence Process

    Rigorous Due Diligence Process Initial Commercial Assessment (Secondary market data, literature review, Dx & Tx patterns, etc.) Patient and prescription-based models to predict commercial potential Refine model through primary research with thought leaders and physicians DUE DILIGENCE Medical Clinic

  33. Slide 33: Late Stage Branded Portfolio

    Slide 33: Late Stage Branded Portfolio

    Late Stage Branded Portfolio Late Stage Investments in Pipeline Accelerates Branded Strategy Product Indication Phase I Phase II Phase III Target NDA Filing Approved Loramyc(tm) Zensana(tm) AndroGel(r) * Megace(r) ES CINV & PONV Oral Candidiasis Testosterone Replacement Therapy Anorexia, Cachexia, o

  34. Slide 34: Megace ES: Excellent Foundation Product

    Slide 34: Megace ES: Excellent Foundation Product

    Megace ES: Excellent Foundation Product Improved formulation of megestrol acetate oral suspension utilizing NanoCrystal(r) Technology (Elan) Approved July 2005 via 505(b)(2) regulatory pathway Indicated for anorexia, cachexia, or unexplained weight loss in AIDS patients Primary focus on conversion o

  35. Slide 35: Megace ES: Offering Multiple Benefits

    Slide 35: Megace ES: Offering Multiple Benefits

    Megace ES* 625mg/5 mL Megace 800mg/20mL Fasting 1041 187 Megace ES: Offering Multiple Benefits Megace ES offers: Bioavailability for unfed patients 1 teaspoon vs. 4 teaspoons QD dosing Less viscous Mean Cmax (ng/mL) Bioavailability in Fasted-State * Extrapolated from 2 single-center bioavailability

  36. Slide 36: Megace ES: TRx Actuals

    Slide 36: Megace ES: TRx Actuals

    +32% +10% Q3 05 Q4 05 Q1 06 Q2 06 Q3 06 Q4 06 Q1 07 Q2 07 Q3 LE Q4 JULY LE MES TRXs 4250 13108 19869 28460 37612 41224 44160 49098 54255 58438 Megace ES: TRx Actuals % growth vs. prior qtr ~$19M Q2 net sales +11% +7% +51% +308% +43% Source: IMS Health

  37. Slide 37: Loramyc (miconazole Lauriad) Overview

    Slide 37: Loramyc (miconazole Lauriad) Overview

    Loramyc (miconazole Lauriad) Overview Miconazole buccal tablet (Lauriad) in development for oropharyngeal candidiasis (OPC) U.S. commercialization rights from Bioalliance with right to advise on development program $15M upon execution, $20M FDA approval milestone, royalties and sales milestones Canc

  38. Slide 38: Zensana (ondansetron) Overview

    Slide 38: Zensana (ondansetron) Overview

    Zensana (ondansetron) Overview Unique, oral spray formulation of ondansetron in development for CINV, RINV, PONV Acquired North American commercial rights from Hana Biosciences; Entered collaboration agreement with Novadel to reformulate Zensana $5M equity investment in Hana, milestone payments and

  39. Slide 39: Pafuramidine Overview

    Slide 39: Pafuramidine Overview

    Pafuramidine Overview Novel antimicrobial agent in Phase III development for pneumocystis pneumonia in AIDS patients U.S. commercialization rights from Immtech for PCP with right to advise on development program $3M upon execution, $29M in potential development milestones, royalties and potential sa

  40. Slide 40: Well-Positioned to Achieve Long-Term Goals

    Slide 40: Well-Positioned to Achieve Long-Term Goals

    Well-Positioned to Achieve Long-Term Goals Develop Branded Division identity Drive Megace ES sales growth and profitability Successfully commercialize pipeline Accelerate growth through in- licensing Launch Strativa Pharmaceuticals Excellence in sales and marketing execution Invest in additional lat

  41. Slide 41: Financial Update

    Slide 41: Financial Update

    Financial Update Gerard A. Martino Executive Vice President and COO

  42. Slide 42: Progress on Financial Reporting

    Slide 42: Progress on Financial Reporting

    Progress on Financial Reporting Key Financial Milestones Dates 2005 10-K/A filed March 13, 2007 10-Q/As for first and second quarters of 2006 filed July 10, 2007 10-Q/A for third quarter of 2006 filed July 30, 2007 10-K for 2006 September 6, 2007 Form 10-Q for first and second quarters of 2007 Earli

  43. Slide 43: Estimated Operating Results For Months Ended 06/30/07

    Slide 43: Estimated Operating Results For Months Ended 06/30/07

    Estimated Operating Results For 6 Months Ended 06/30/07 RANGE (in millions except per share amounts) ONE-TIME ITEMS Revenues $390 - $395 Gross Margin $140 - $143 R&D $28 $(3) Pafuramidine SG&A $65 $(2) Severance Other Income, Net $15 $21 PAR 101 $(6) High Yield Inv Loss Pre-tax Income $62 - $65 Net

  44. Slide 44: Estimated Sales Highlights For Months Ended 06/30/07

    Slide 44: Estimated Sales Highlights For Months Ended 06/30/07

    Estimated Sales Highlights For 6 Months Ended 06/30/07 PRODUCT SALES (in millions) Fluticasone $95 Propanolol 42 Megace ES 36 Metropolol 30 Amoxicillin 25 Cabergoline 18 Other Product Related Revenues: Androgel co-promotion 5 Ondansetron Royalties 8

  45. Slide 45: Estimated Operating Results For Full Year 2007

    Slide 45: Estimated Operating Results For Full Year 2007

    Estimated Operating Results For Full Year 2007 Expected Second Half Impacts: Competition on Product Sales: Fluticasone Propanolol Cabergoline Ondansetron Royalties Revenues $730 - $765 million

  46. Slide 46: Estimated Operating Results For Full Year 2007

    Slide 46: Estimated Operating Results For Full Year 2007

    Estimated Operating Results For Full Year 2007 IMPACT OF ONE-TIME ITEMS (in millions, except per share amounts) FY 2007 Severance $2 Branded Milestone Payments 19 High Yield Investment Loss 6 PAR 101 (21) Total One-Time Items $6 EPS Impact (fully diluted) $0.10 EPS (fully diluted) adjusted for one-t

  47. Slide 47: Strong Balance Sheet

    Slide 47: Strong Balance Sheet

    Strong Balance Sheet (in millions) 06/30/07 12/31/06 CURRENT ASSETS: Cash, equivalents and available for sale securities $342 $213 Accounts receivable, net 37 95 Inventories 86 106 Total current assets: $564 $514 Total non-current assets: $263 $296 CURRENT LIABILITIES: Short-term and current portion

  48. Slide 48: Stock Repurchase Program

    Slide 48: Stock Repurchase Program

    Stock Repurchase Program Strong balance sheet position Confidence in company's strategy and long-term outlook Board approved $75 million stock repurchase program 10% of outstanding shares at today's price

  49. Slide 49: The "New" Par Pharmaceutical

    Slide 49: The "New" Par Pharmaceutical

    The "New" Par Pharmaceutical Refocused strategy Proven successful execution Leading mid-size Generics business Growing Branded business with strong product pipeline Sustainable business processes in place to drive long-term growth and profitability Leading to Greater Transparency for Investors

  50. Slide 50: Milestones to Continued Success

    Slide 50: Milestones to Continued Success

    Milestones to Continued Success 6 - 10 first-to-files per year >50% of products to come from internal development Increase gross margins Continue AG opportunities Accelerate brand growth Additional in-licensed products Continue growth in Megace ES >$250 million in annualized sales GENERIC BUSINESS B

  51. Slide 51: Question & Answer Session

    Slide 51: Question & Answer Session

    Question & Answer Session

  52. Slide 52: Par Pharmaceutical Analyst / Investor Day

    Slide 52: Par Pharmaceutical Analyst / Investor Day

    Par Pharmaceutical Analyst / Investor Day September 28, 2007 Focus - Execution - Value

Source: SEC EDGAR · 8-K filed Sep 28, 2007

More decks from Par Pharmaceutical Companies Inc